Most Read Articles
one year ago
Cannabinoid hyperemesis syndrome (CHS) should be regarded as an important differential diagnosis in recurrent nausea and vomiting, according to a retrospective cohort study .
Jackey Suen, one year ago
Several biomarker candidates may improve screening and monitoring of treatment response in colorectal cancer (CRC), inflammatory bowel disease (IBD) and hepatocellular carcinoma (HCC), say experts of the Department of Medicine and Therapeutics, Chinese University of Hong Kong (CUHK), at the CUHK’s Advances in Medicine 2015 conference.
one year ago
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.
one year ago
In an exclusive interview with MIMS Doctor, renowned gastroenterologists from Subang Jaya Medical Centre, Dr Tan Soon Seng and Dr Ranjeev C K Prabhakeran,
shared their perspectives and experiences on the use of Fuse® (Full Spectrum Endoscopy) in their clinical practice. Both of them have been practicing gastroenterology
for almost 20 years and have completed more than 1,200 procedures using the Fuse® system.

Fuse® has been available in Malaysia since January 2015. Subang Jaya Medical Centre is the first medical centre in Asia and the ONLY one in Malaysia to use the
Fuse® at the present moment. As cited in The Lancet Oncology,1 March 2014, Fuse® Endoscopy System detected 69% more pre-cancerous polyps than standard forwardviewing colonoscopy.

Azathioprine effectively maintains remission in autoimmune pancreatitis

8 days ago

Treatment with azathioprine (AZA) appears to safely and effectively prevent autoimmune pancreatitis (AIP) relapses, according to a retrospective study.

The study included AIP patients who were treated with AZA (AZA+ group; n=23; mean age 54 years; 78 percent male) as maintenance therapy or did not receive maintenance therapy (AZA− group; n=97; mean age 45 years; 59.8 percent male). None of the patients had previous pancreatic surgery, other autoimmune diseases as indication for AZA treatment, and used immunosuppressants (IMs) other than AZA. Evaluations included drug safety and clinical and instrumental outcomes of patients in the AZA+ group.

Patient characteristic data showed that compared with those in the AZA− group, AZA+ group patients were significantly older (p=0.043), more likely to have type 1 AIP (87 vs 51 percent; p=0.006), higher sIgG4 (758 vs 311 mg/dl; p<0.001), other organ involvement (OOI; 83 vs 48 percent; p=0.002) and higher frequency of relapse prior to AZA treatment (78 vs 14 percent; p<0.001).

Drug discontinuation due to adverse events (AEs) was reported in three patients in the AZA+ group. Of the 20 patients available for outcome evaluation, six relapsed after 24 months (30 percent; five in pancreas and one on biliary tract). Those who relapsed received retreatment with steroids and continued AZA. Second relapse was reported in two patients (33 percent), occurring after 11 months (in pancreas and kidney) in one and after 22 months (in kidney) in the other.

Based on the present data, researchers said AZA use may be considered in relapsing type 1 AIP and/or in the presence of other organ’s involvement and elevated IgG4 at clinical onset.

Having unique histological features, AIP has two histological subtypes. Type 1 is characterized by periductal infiltration of lymphocytes, abundant IgG4-positive plasma cells in pancreatic parenchyma, storiform fibrosis and obliterative phlebitis. This AIP type is commonly diagnosed in elderly males and is associated with high IgG4 serum levels, extra pancreatic involvement (biliary tree, salivary glands, kidney, retroperitoneum) and frequent relapses. On the other hand, type 2 AIP is characterized by the presence of granulocytic epithelial lesions, whereas IgG4-positive plasma cells are rare or absent in pancreatic parenchyma. This AIP type commonly affects younger individuals, and inflammatory bowel disease is a common observation; relapses after steroids are rare. [Virchows Arch 2004;445:552–563; Pancreas 2010;39:549–554; Pancreas 2011;40:1172–1179; Gastroenterology 2010;139:140–148; Pancreatology 2012;12:276–283]

Editor's Recommendations
Most Read Articles
one year ago
Cannabinoid hyperemesis syndrome (CHS) should be regarded as an important differential diagnosis in recurrent nausea and vomiting, according to a retrospective cohort study .
Jackey Suen, one year ago
Several biomarker candidates may improve screening and monitoring of treatment response in colorectal cancer (CRC), inflammatory bowel disease (IBD) and hepatocellular carcinoma (HCC), say experts of the Department of Medicine and Therapeutics, Chinese University of Hong Kong (CUHK), at the CUHK’s Advances in Medicine 2015 conference.
one year ago
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.
one year ago
In an exclusive interview with MIMS Doctor, renowned gastroenterologists from Subang Jaya Medical Centre, Dr Tan Soon Seng and Dr Ranjeev C K Prabhakeran,
shared their perspectives and experiences on the use of Fuse® (Full Spectrum Endoscopy) in their clinical practice. Both of them have been practicing gastroenterology
for almost 20 years and have completed more than 1,200 procedures using the Fuse® system.

Fuse® has been available in Malaysia since January 2015. Subang Jaya Medical Centre is the first medical centre in Asia and the ONLY one in Malaysia to use the
Fuse® at the present moment. As cited in The Lancet Oncology,1 March 2014, Fuse® Endoscopy System detected 69% more pre-cancerous polyps than standard forwardviewing colonoscopy.